Department of Surgery, Yokohama City University, Yokohama, Japan;
Department of Surgery, Yokohama City University, Yokohama, Japan.
Anticancer Res. 2022 May;42(5):2711-2717. doi: 10.21873/anticanres.15749.
BACKGROUND/AIM: Perioperative systemic inflammation affects the long-term oncological outcomes in cases of malignancies. We evaluated the clinical impact of the preoperative systemic inflammation score (SIS) in resectable esophageal cancer patients who received curative treatment.
This study included 168 patients who underwent curative surgery followed by perioperative adjuvant chemotherapy for esophageal cancer between 2005 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified.
Based on the 3- and 5-year OS rate, we set the cut-off value for SIS at 2 in the preset study. Among the 168 total patients, 119 were categorized as the Low-SIS group, and 49 were categorized as the High-SIS group. The respective 3- and 5-year OS rates were 61.9% and 52.4% in the Low-SIS group and 33.3% and 26.6% in the High-SIS group. There were significant differences in OS (p<0.001). The SIS was therefore selected for the final multivariate analysis model (hazard ratio=2.094, 95% confidence interval=1.355-3.234, p<0.001). On comparing the perioperative clinical course between the High- and Low-SIS groups, there were significant differences in the rate of postoperative anastomosis leakage of grade ≥2 between the groups (61.5% in the High-SIS group vs. 30.3% in the Low-SIS group; p=0.021).
The systemic inflammation score had a clinical effect on the long-term oncological outcomes in esophageal cancer patients, suggesting that it might be a promising prognostic factor for esophageal cancer patients.
背景/目的：围手术期全身炎症反应会影响恶性肿瘤患者的长期肿瘤学预后。我们评估了术前全身炎症评分（SIS）在接受根治性治疗的可切除食管癌患者中的临床影响。
本研究纳入了 168 例于 2005 年至 2018 年期间接受根治性手术和围手术期辅助化疗的食管癌患者。确定了总生存期（OS）和无复发生存期（RFS）的危险因素。
基于 3 年和 5 年 OS 率，我们在预设研究中将 SIS 的截断值设定为 2。在 168 例患者中，119 例患者被归类为低 SIS 组，49 例患者被归类为高 SIS 组。低 SIS 组的 3 年和 5 年 OS 率分别为 61.9%和 52.4%，高 SIS 组的 3 年和 5 年 OS 率分别为 33.3%和 26.6%。OS 存在显著差异（p<0.001）。因此，SIS 被选入最终的多变量分析模型（风险比=2.094，95%置信区间=1.355-3.234，p<0.001）。比较高 SIS 组和低 SIS 组的围手术期临床过程，两组术后吻合口漏发生率存在显著差异（高 SIS 组为 61.5%，低 SIS 组为 30.3%；p=0.021）。
全身炎症评分对食管癌患者的长期肿瘤学预后有临床影响，表明其可能是食管癌患者有前途的预后因素。
